Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

计划入组 117 人 · 首次发布于 2017 年 7 月 18 日

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

计划入组 38 人 · 首次发布于 2020 年 10 月 29 日

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

计划入组 54 人 · 首次发布于 2026 年 8 月 11 日

CH505 TF chTrimer

CH505 M5(NIAID)

CH505TF gp120(NIAID)

Accelerated Manufacturing Platform Enables Rapid HIV Vaccine Production for Clinical Trials

RESTART Trial Launches to Test Novel HIV Treatment Targeting Toxic Viral Protein gp120

Novel HIV Vaccine Shows 97% Antibody Response Rate in Phase 1 Trial